EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A 3rd; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL; Nature, 2012, vol. 492, issue 7427, p 108, ISSN 14764687. ISBN 14764687.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef